This focused issue on “The Management of Thyroid Tumors in 2020 and Beyond” is edited by Dr. Jeremy D. Richmon, from Department of Otolaryngology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; and Jonathon O Russell, from Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USA.
Dr. Jeremy Richmon is a fellowship-trained head and neck surgeon who specializes in head and neck cancer and microvascular reconstruction. He has become a pioneer in minimally-invasive robotic techniques in the head and neck. He was the first surgeon to perform transoral robotic surgery at Johns Hopkins in 2009 and developed a robust head and neck robotic surgery program of international renown. He has collaborated with engineers and computer scientists to bring the next generation of robotics into the clinical realm and began the robotic thyroid surgery program at Johns Hopkins.
Dr. Jonathon O Russell is an Assistant Professor of Head and Neck Endocrine Surgeon and the Director of Endoscopic and Robotic Thyroid and Parathyroid Surgery at Johns Hopkins. As such, he manages the broad range of thyroid and parathyroid surgical pathology and specializes in scarless transoral thyroidectomy and parathyroidectomy. His treatment philosophy is that every patient deserves an individualized treatment strategy and that communication between physician and patient is the most important part of the healing process.
- Focused issue outline:
- Preface: the management of thyroid tumors in 2020 and beyond
Jonathon Russell, Johns Hopkins, Baltimore, USA and Jeremy Richmon, Harvard Medical School, Boston, USA - Parathyroid auto-fluorescence
Kang Dae Lee, Kosin University College of Medicine, Busan, South Korea - Active surveillance review
Emad Kandil, Tulane University, New Orleans, USA - Nerve monitoring review
Joseph Scharpf, Cleveland Clinic, Cleveland, USA
Vaninder K. Dhillon, Johns Hopkins, Baltimore, USA
Catherine F. Sinclair, Mount Sinai West, New York, USA - Radio frequency ablation for benign lesions
Leonardo Rangel, State University of Rio de Janeiro, Rio de Janeiro, Brazil - Artificial intelligence review vs original
Young Jun Chai, Seoul National University Boramae Medical Center, Seoul, South Korea - Telemedicine/Pt satisfaction review
Christopher Britt, Loyola University, Chicagao, USA
Estelle Chang, Montefiore Medical Center, New York, USA - TKIs
Christopher Britt, Loyola University, Chicago, USA - Candidacy for TOETVA
Raymon Grogan, Baylor University, Waco, USA
Insoo Suh, University of California, San Francisco, San Francisco, USAJonathon Russell, Johns Hopkins, Baltimore, USA - Starting an inner city TOETVA program – patient recruitment strategies
Victoria Banuchi, Weill Cornell Medical College, New York, USA - TOETVA vs BABA
Hyunsuk Suh, William B. Inabnet III and Gustavo Fernandez-Ranvier, Mount Sinai West, New York, USA - Using social media to build an endocrine surgery practice
Allen Ho, Cedars-Sinai Medical Cancer, Los Angeles, USA - Single port robot experience
Ralph Tufano, Johns Hopkins, Baltimore, USA; Hoon Yub Kim, Korea University, Seoul, South Korea - Perioperative utilization of AI/surgical aids
Chris Holsinger, Stanford University School of Medicine, Stanford, USA - Robotic autonomy
Ryan Orosco, University of California San Diego, La Jolla, USA - Simulations and simulators for endocrine surgery
Christopher R. Razavi and Jonathon Russell, Johns Hopkins, Baltimore, USA
Jeremy Richmon, Harvard Medical School, Boston, USA
Disclosure:
The series “The Management of Thyroid Tumors in 2020 and Beyond” was commissioned by the editorial office, Annals of Thyroid without any sponsorship or funding. Jeremy D. Richmon and Jonathon O Russell are serving as the unpaid Guest Editors for the series.
